Ticker	Current Price	Change	Graph
IBB	109.46	2.77 (2.47%)
XBI	95.93	3.15 (3.18%)

Insiders, IPOs

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

Results

Oops. Pfizer's CDK 4/6 blockbuster Ibrance flunks the OS mark for breast cancer

CAR-T, Collaborations

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

Latest

FDA to release list of surrogate endpoints in oncology →

BREAKING: FDA OKs first cannabinoid, gives green light to GW Pharma’s Epidiolex for rare seizures →

Food-sourced microbiome drugs get $101M megaround for Flagship's Kaleido →

Sudden death forces Sophiris to halt followup therapy in prostate cancer study — shares crushed →

Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat →

Akero elbows its way into a crowded NASH field, with $65M and a strategy for tackling a blockbuster market →

Roche’s Tecentriq scoops up a big win in small cell lung cancer, grabbing the lead in frontline cases →

UK startup NodThera banks a $40M round with plans to conquer a closely-studied inflammatory target →

A slimmer FDA: White House proposes 30% cut to headcount under reorganization →

Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain →

Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires →

J&J opens up a new biotech incubator, polishing the Big Apple's ambitions to create a major hub →

Top News

In high-level reshuffle, Roche gives James Sabry the global reins on deal-making — overseeing pRED and gRED

John Carroll

Autolus extends the biotech IPO hot streak, adding $150M and bringing 2-day tally to $718M

John Carroll

Mauled by a major setback, Incyte is pointing to a better future — but concedes it also had to scrap another failed study

John Carroll

Novo Nordisk’s 'sema' whips Merck’s diabetes drug rival in PhIII as it reaches for best-in-class ranking for GLP-1 group

John Carroll

Six biotechs crowd into Nasdaq, raising $568M as the IPO party continues to lure companies to Wall Street

John Carroll

More news

Protocols

Quick hits from around the biopharma web

Jun 25

Dementia Discovery Fund closes $350M, recruits Celgene exec as CEO; Ex-Lazard banker Ian Woo joins C-Bridge and Everest

Jun 22

Nanobiotix shares rocket up on a marginal success for soft tissue sarcoma; AstraZeneca wins pioneering PD-L1 OK in India

Jun 21

AdoRx raises $10M for adenosine program in cancer; Molecular Partners poaches Regeneron, recruiting Pamela Trail as CSO

Jun 20

Celgene/Receptos exec jumps to Kura as new COO; TG Therapeutics allies with Novimmune on $185M bispecific deal

More Protocols

Premium

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Where does the science come from? The top 20 NIH-funded institutions in 2017

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Marco

Hot BioTwitter bot - last updated ago

Most Viral

BREAKING: FDA OKs first cannabinoid, gives green light to GW Pharma's Epidiolex for rare seizures

ENDPOINTS NEWS John Carroll a day

A Drug Costs $272,000 a Year. Not So Fast, Says New York State.

New York Times a day

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

ENDPOINTS NEWS John Carroll a day

The 39 best health and science books to read this summer

STAT a day

Tweeting Oncologist Draws Ire And Admiration For Calling Out Hype

NPR.org Richard Harris a day

EPIDIOLEX Label

FDA a day

Xconomy: With Roche Data, Cancer Combos Post First Win Vs. Small Cell Lung Cancer

Xconomy Ben Fidler a day

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

ENDPOINTS NEWS Brittany Meiling a day

Dementia Discovery Fund closes $350M, recruits Celgene exec as CEO; Jardiance impresses on PhIII diabetes data

ENDPOINTS NEWS Brittany Meiling a day

The Trump Appointee Who's an Addiction Specialist

New York Times a day

Latest

The BMJ

Richard Lehman's journal review-25 June 2018 - The BMJ

Malibu Times

Sunday Update: Malibu Canyon Murder Victims ID's As Irvine Research Scientist, Father

Bloomberg

First Marijuana-Based Medicine Is Approved for Sale in U.S.

FDA

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

ENDPOINTS NEWS

BREAKING: FDA OKs first cannabinoid, gives green light to GW Pharma's Epidiolex for rare seizures

FDA

EPIDIOLEX Label

Renaissance Capital

Rare endocrine disease biotech Crinetics Pharmaceuticals files for an $86 m - Renaissance Capital

Chemical & Engineering News

AbbVie invests in switchable CAR-T therapies for cancer

Chimeraresearchgroup

PSTI - Placenta Stem-Cells Brings Hope to PAD-Peripheral Artery Disease Patients

GEN

Gut Microbiome Understanding Insight Facilitated by New Platform | GEN

Hot This Week

1

STAT

Here come the right-to-try profiteers. The FDA is powerless to stop them

2

Roche

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology

3

Nature

New human gene tally reignites debate

4

ENDPOINTS NEWS

In high-level reshuffle, Roche gives James Sabry the global reins on deal-making - overseeing pRED and gRED

5

Bloomberg

Finding Cancer Patients Is Pharma Industry's Unlikely Challenge

6

STAT

Atul Gawande picked as CEO of Amazon, Berkshire health care company

7

STAT

Sarepta's gene therapy for Duchenne raises hopes for 'real change'

8

Reveal

Immigrant children forcibly injected with drugs, lawsuit claims

9

In the Pipeline

Welcome to Right to Try

10

CNBC

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

Oops. Pfizer's CDK 4/6 blockbuster Ibrance flunks the OS mark for breast cancer

After Rova-T bust, AbbVie plans new solid tumor assault, licensing next-gen CAR-T tech from Calibr

Latest

FDA to release list of surrogate endpoints in oncology →

BREAKING: FDA OKs first cannabinoid, gives green light to GW Pharma’s Epidiolex for rare seizures →

Food-sourced microbiome drugs get $101M megaround for Flagship's Kaleido →

Sudden death forces Sophiris to halt followup therapy in prostate cancer study — shares crushed →

Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat →

Akero elbows its way into a crowded NASH field, with $65M and a strategy for tackling a blockbuster market →

Roche’s Tecentriq scoops up a big win in small cell lung cancer, grabbing the lead in frontline cases →

UK startup NodThera banks a $40M round with plans to conquer a closely-studied inflammatory target →

A slimmer FDA: White House proposes 30% cut to headcount under reorganization →

Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain →

Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires →

J&J opens up a new biotech incubator, polishing the Big Apple's ambitions to create a major hub →

Sponsored

Minimal Residual Disease: A Prognostic Factor Moving the Needle in Patient Care

Top News

Protocols

Premium

What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M

The 2-trial hurdle for drug approvals is steadily losing ground. Are we devaluing the industry's R&D gold standard?

Where does the science come from? The top 20 NIH-funded institutions in 2017

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

Bristol-Myers offers some eagerly awaited Checkmate-227 results, but they're not changing medical practice -- yet

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password